These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 16021867)

  • 21. Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients.
    Winters MA; Bosch RJ; Albrecht MA; Katzenstein DA;
    J Infect Dis; 2003 Aug; 188(4):537-40. PubMed ID: 12898440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8.
    Cassol E; Page T; Mosam A; Friedland G; Jack C; Lalloo U; Kopetka J; Patterson B; Esterhuizen T; Coovadia HM
    J Infect Dis; 2005 Feb; 191(3):324-32. PubMed ID: 15633090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
    AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial.
    Fox Z; Dragsted UB; Gerstoft J; Phillips AN; Kjaer J; Mathiesen L; Youle M; Katlama C; Hill A; Bruun JN; Clumeck N; Dellamonica P; Lundgren JD;
    Antivir Ther; 2006; 11(6):761-70. PubMed ID: 17310820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine.
    Marcelin AG; Flandre P; Furco A; Wirden M; Molina JM; Calvez V;
    Antivir Ther; 2006; 11(6):693-9. PubMed ID: 17310813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
    Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
    J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virologic and immunologic response to nucleoside reverse-transcriptase inhibitor therapy among human immunodeficiency virus-infected infants and children.
    Palumbo PE; Raskino C; Fiscus S; Pahwa S; Schutzbank T; Spector SA; Baker CJ; Englund JA
    J Infect Dis; 1999 Mar; 179(3):576-83. PubMed ID: 9952363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug.
    Lori F; Lisziewicz J
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S193-7. PubMed ID: 10860905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
    Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
    Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is Hydroxyurea for real?
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):6-16, 18. PubMed ID: 11365731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
    Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
    Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006.
    Lalezari JP; Ward DJ; Tomkins SA; Garges HP
    J Antimicrob Chemother; 2007 Jul; 60(1):170-4. PubMed ID: 17491001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens.
    Negredo E; Garrabou G; Puig J; Lòpez S; Morén C; Bellido R; Ayen R; Cardellach F; Miró O; Clotet B
    Antivir Ther; 2008; 13(2):231-40. PubMed ID: 18505174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An additive/subtractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients.
    Capdepont S; Aurillac-Lavignolle V; Faure M; Dupon M; Morlat P; Ragnaud JM; Chêne G; Fleury H; Masquelier B;
    J Clin Virol; 2006 May; 36(1):36-42. PubMed ID: 16513416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of didanosine in the management of HIV-1 infection.
    Gazzard BG; Moyle GJ
    Antivir Ther; 1997 Jul; 2(3):135-47. PubMed ID: 11322269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV treatment options.
    Smith D
    AIDS Treat News; 1998 May; (No 294):4-5. PubMed ID: 11365404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
    Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Standard treatments for HIV, Spring 1997.
    Smith D
    AIDS Treat News; 1997 Apr; (No 269):4-5. PubMed ID: 11364255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
    Ananworanich J; Hill A; Siangphoe U; Ruxrungtham K; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Nuesch R; Cooper DA; Hirschel B;
    Antivir Ther; 2005; 10(6):761-7. PubMed ID: 16218176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.